Results 41 to 50 of about 929,693 (286)

Comparison of lentiviral and sleeping beauty mediated αβ T cell receptor gene transfer.

PLoS ONE, 2013
Transfer of tumour antigen-specific receptors to T cells requires efficient delivery and integration of transgenes, and currently most clinical studies are using gamma retroviral or lentiviral systems.
Anne-Christine Field, Conrad Vink, Richard Gabriel, Roua Al-Subki, Manfred Schmidt, Nicholas Goulden, Hans Stauss, Adrian Thrasher, Emma Morris, Waseem Qasim   +9 more
doaj   +1 more source

Clinical implications of antigen transfer mechanisms from malignant to dendritic cells: Exploiting cross-priming [PDF]

, 2002
Expansion and activation of cytolytic T lymphocytes bearing high-affinity T-cell receptors specific for tumor antigens is a major goal of active cancer immunotherapy.
Alfaro, C. (Carlos), Arina, A. (Ainhoa), Bendandi, M. (Maurizio), Feijoo, E. (Esperanza), Inoges, S. (Susana), Lopez, A. (Ascensión), Mazzolini, G. (Guillermo), Melero, I. (Ignacio), Rodriguez-Calvillo, M. (Mercedes), Tirapu, I. (Íñigo)   +9 more
core   +1 more source

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

Acta Pharmaceutica Sinica B, 2018
Chimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR).
Zijun Zhao, Yu Chen, Ngiambudulu M. Francisco, Yuanqing Zhang, Minhao Wu   +4 more
doaj   +1 more source

Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy [PDF]

, 2016
Due to the lack of specificity for tumor antigens, allogeneic T-cell therapy is associated with graft-versus-host disease. Enhancing the anti-tumor specificity while reducing the graft-versus-host disease risk of allogeneic T cells has remained a ...
Chakraverty, R, Ghorashian, S, Holler, A, Hotblack, A, Morris, EC, Pike, R, Stauss, HJ, Velica, P, Xue, S-A, Zech, M   +9 more
core   +3 more sources

T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies

Nature Communications, 2022
AbstractThe success of chimeric antigen receptor (CAR) T cells in treating B cell malignancies comes at the price of eradicating normal B cells. Even though T cell malignancies are aggressive and treatment options are limited, similar strategies for T cell malignancies are constrained by the severe immune suppression arising from bystander T cell ...
Fanlin Li, Huihui Zhang, Wanting Wang, Puyuan Yang, Yue Huang, Junshi Zhang, Yaping Yan, Yuan Wang, Xizhong Ding, Jie Liang, Xinyue Qi, Min Li, Ping Han, Xiaoqing Zhang, Xin Wang, Jiang Cao, Yang-Xin Fu, Xuanming Yang   +17 more
openaire   +3 more sources

Expression of interleukin 2 receptors on activated human B cells. [PDF]

, 1984
Using anti-Tac, a monoclonal anti-interleukin 2 (IL-2) receptor antibody, we have explored the possibility that certain activated B cells display receptors for IL-2.
Bongiovanni, KF, Depper, JM, Goldman, CK, Greene, WC, Korsmeyer, SJ, Leonard, WJ, Robb, RJ, Sharrow, SO, Waldmann, TA   +8 more
core  

T-cell cytotoxicity in the absence of viral protein synthesis in target cells [PDF]

, 1977
CYTOTOXIC T cells lyse only those virus infected target cells in vitro which express, in addition to the viral antigen(s), those K or D region products of the major histocompati-bility complex (MHC) which were present during anti-viral sensitisation in ...
A Munro, A Scheid, BH Sandford, BK Ray, D Aminoff, F Garrido, GI Ada, H Ertl, ID Gardner, J Neff, J Salk, M. J. GETHING, M. WATERFIELD, U Koszinowski, U. KOSZINOWSKI, UK Laemmli, Y Hosaka, Y Ueda, YK Shimizu   +18 more
core   +1 more source

Improved Outcomes for Older Children, Adolescents, and Young Adults With Neuroblastoma in the Post‐Immunotherapy Era: An Updated Report From the International Neuroblastoma Risk Group

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background We describe clinical and biologic characteristics of neuroblastoma in older children, adolescents, and young adults (OCAYA); describe survival outcomes in the post‐immunotherapy era; and identify if there is an age cut‐off that best discriminates outcomes.
Rebecca J. Deyell, Kavitha Srivatsa, Paola Angelini, Pei‐Chi Kao, Brady Payne, Arlene Naranjo, Sveva Castelli, Miho Kato, Miki Ohira, Ulriche Pöetschger, Yaël Mossé, Lucas Moreno, Meredith S. Irwin, Ramya Ramanujachar, Wendy B. London   +14 more
wiley   +1 more source

Antibody-gamma/delta T cell receptors targeting GPC2 regress neuroblastoma with low antigen density

Cell Reports Medicine
Summary: Chimeric antigen receptor (CAR) T cells have shown promise in hematological cancers but face challenges in solid tumors, partly due to heterogeneous antigen density. Glypican-2 (GPC2) is an oncofetal antigen highly expressed in neuroblastoma and
Alex Quan, Mingyu Huo, Dan Li, Laura E. Hutchins, Constanza Rodriguez, Jangsuk Oh, Hsi-En Tsao, Madeline Spetz, Elijah Edmondson, Dana Ashworth, Rui Zheng, Jing Zhou, Jinyun Chen, Jingbao Liu, Guangyan Xiong, Hongbing Zhang, Cheng Liu, Rosa Nguyen, Nan Li, Mitchell Ho   +19 more
doaj   +1 more source

Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. [PDF]

, 2017
T-cells play a critical role in tumor immunity. Indeed, the presence of tumor-infiltrating lymphocytes is a predictor of favorable patient prognosis for many indications and is a requirement for responsiveness to immune checkpoint blockade therapy ...
Ackerman, Ahmed, Ansell, Araki, Ascierto, Beatty, Beatty, Blagih, Borkner, Brahmer, Brandacher, Brentjens, Brentjens, Bridgeman, Brocker, Brudno, Buck, Buckanovich, Burnette, Butler, Butler, Carpenito, Caruana, Caruso, Chang, Chang, Chen, Chen, Chen, Cherkassky, Chmielewski, Church, Colegio, Cordoba, Cretenet, Crompton, Cui, Curiel, Curran, Deaglio, Demaria, Doedens, Facciabene, Fesnak, Finney, Fischer, Fousek, Fox, Frauwirth, Frauwirth, Fridman, Fuertes, Gabrilovich, Gajewski, Gajewski, Galon, Gargett, Gattinoni, Gattinoni, Gattinoni, Geiger, Geissmann, Gill, Gobert, Govers, Gracias, Grada, Gross, Gross, Gubin, Gubser, Guest, Guppy, Hall, Hamanishi, Han, Harlin, Herrera, Hinrichs, Hinrichs, Ho, Hodi, Hombach, Hombach, Hombach, Hsu, Huang, Hudecek, Hwang, Iida, Ino, Irving, Italiani, James, Jass, Jensen, Jensen, Ji, Jones, Joyce, June, Justus, Kahlon, Kawalekar, Kerkar, Kershaw, Kershaw, Khalil, Khalil, Klebanoff, Klebanoff, Klebanoff, Klug, Lamers, Lanitis, Lanitis, Larkin, Le, Le, Lee, Li, Lipson, Liu, Liu, Lochner, Long, Louis, Lugli, Lunt, MacIver, Mahoney, Martinez-Forero, Marvel, Maude, Maus, Maus, Mellor, Menetrier-Caux, Mikucki, Miller, Mittal, Moon, Morgan, Morgan, Morsut, Motz, Motz, Motzer, Muniappan, Munn, Munn, Munn, Murdoch, Nghiem, Niederman, Noman, Okamoto, Otsuji, O’Sullivan, O’Sullivan, Palazón, Palmer, Pameijer, Pandiyan, Paolino, Pardoll, Parry, Patsoukis, Pearce, Pegram, Peng, Peng, Pipkin, Pluta, Porter, Powles, Prosser, Rabinovich, Rathmell, Restifo, Rizvi, Rodriguez, Rodriguez, Rosenberg, Rosenberg, Roybal, Salerno, Sallusto, Santoro, Savoldo, Scharping, Schmid, Schwartz, Semenza, Sharpe, Sikalidis, Sinclair, Singh, Sivan, Smith, Snyder, Sommermeyer, Spranger, Spranger, Spranger, Srivastava, Stromnes, Suarez, Sukumar, Sukumar, Tamada, Tan, Taylor, Terakura, Topalian, Topalian, Topalian, Torikai, Tran, Tumeh, Turatti, Urbanska, Uyttenhove, van der Merwe, van der Waart, van der Windt, van der Windt, van der Windt, van Rooij, Vander Heiden, Vuillefroy de Silly, Vuillefroy de Silly, Vétizou, Waickman, Wang, Wang, Wang, Wang, Wang, Warburg, Wherry, Willemsen, Wing, Wofford, Wu, Xu, Yang, Yang, Yaqoob, Zhang, Zhang, Zhang, Zheng   +252 more
core   +1 more source